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Short-term efficacy and safety of antithymocyte globulin
treatment in elderly patients with acquired aplastic anaemia
Guidelines for the diagnosis and management of adult aplastic
anaemia patients were published recently on behalf of the Bri-
tish Society for Standards in Haematology (Killick et al, 2016).
The combination of horse-derived anti-thymocyte globulin
(ATG) and ciclosporin (CSA) is considered to be the standard
first-line immunosuppressive therapy (IST). However, in
elderly patients (aged ≥ 60 years) it is advised to weigh-up the
risks and benefits of this intensive treatment for each individ-
ual patient as older age is associated with an increased risk of
acute and delayed toxicity of ATG-based treatment and the
overall survival might be worse due to inferior tolerability.
We agree that it is important to look for the right balance
between toxicity and efficacy of an intensive and potential
hazardous treatment, especially in vulnerable patient groups
such as patients aged ≥ 60 years. Unfortunately, data regard-
ing the safety and toxicity of ATG-based treatment schedules
in this age group are scarce. Current recommendations are
partly based on data from the European Society for Blood
and Marrow Transplantation (EBMT) registry. Retrospective
analysis of these data showed a similar response rate but an
inferior overall survival in patients aged ≥ 60 years compared
to younger patients (Tichelli et al, 1999). Within the first
year after IST, 40 deaths were observed among the 127
elderly patients. The majority of these elderly patients
received IST consisting of only CSA or received a reduced
dose of ATG. Data on direct ATG-associated toxicity were
lacking in this study (Tichelli et al, 1999). A single centre
analysis from the National Institute of Health of 316 patients
(including children) showed that age is inversely correlated
with the probability of response at 6 months after IST with
ATG and CSA (Scheinberg et al, 2009). In another retrospec-
tive single centre study, three out of seven elderly patients
who were treated with standard dosed ATG died within a
month after start of the treatment (Kao et al, 2008). In a Bri-
tish multicentre study, 14 elderly patients were treated with a
reduced dose of ATG without CSA, which was associated
with low toxicity. The response rate, however, was
Table I. Patient characteristics and outcomes.
N = 23
Median age, years (range) 64 (60–79)
Median follow-up time, months (range) 12 (1–45)
Male 17 (74%)
Disease severity
Non severe 7 (30%)
Severe 8 (35%)





Survival, % (95% confidence interval)
6 months 96 (88–100)
12 months 88 (73–100)
N = 17




ª 2016 John Wiley & Sons Ltd 459
British Journal of Haematology, 2018, 180, 443–462
Correspondence
disappointing as only one patient achieved a partial haema-
tological response after 6 months (Killick et al, 2006).
The national guidelines from the Dutch Society for Hae-
matology (NVvH) for the diagnosis and treatment of aplastic
anaemia in adult patients recommends first-line treatment
with IST consisting of horse-derived ATG (ATGAM, Pfizer,
New York, NY, USA) at 40 mg/kg/day for 4 days in combi-
nation with oral CSA in patients with acquired aplastic anae-
mia who are not eligible for first-line allogeneic stem cell
transplantation (alloSCT). In order to gain more insight in








(CTCAE-grade) Late complications / Deaths
M 60 S Hypertension,
angina pectoris
0 Angina pectoris (1)
M 60 VS COPD, hypertension,
atrial fibrillation
1 Prolonged QTc interval (1),
acute kidney injury (1–2)
Secondary AML at 40 months,
death at 45 months
due to infection
M 62 NS Hypertension 0 None
M 62 VS None 0 Acute kidney injury (1–2)
M 62 NS None 0 None
M 63 VS None 0 None
M 64 NS None 0 Chronic kidney injury (2)
M 64 S None 0 None
M 64 VS None 0 None Death at 1 month
due to haemorrhagic stroke
M 64 S Hypertension, diabetes,
chronic kidney disease
3 Hypertension (1–2)
F 64 VS None 0 None Death at 10 months due
to complications of
second-line alloSCT
M 64 NS Hypertension, diabetes 1 TRALI after platelet infusion
M 64 S History of treated thymoma 2 Hypertension (1–2), acute
kidney injury (1–2)
M 66 NS COPD, Hypertension,
elevated liver enzymes
2 Hypertension (1–2)
M 66 S Obstructive sleep
apnoea syndrome
0 None




2 Subdural haematoma resulting
in epileptic seizure (2),
systemic infection
M 68 NS None 0 Hypertension (1–2), acute
kidney injury (1–2)
F 69 VS None 0 Pulmonary embolism (3),
atrial fibrillation (1),
chronic kidney injury (2),
systemic infections




3 Atrial fibrillation resulting
in myocardial ischaemia (3),
heart failure (3),
acute kidney injury (1)
M 72 S History of cured
tuberculosis
0 None
F 75 VS Hypertension, TIA 1 Acute kidney injury (1–2)
F 77 S None 0 None
F 79 S Hypertension 0 None
ATGAM, horse-derived anti-thymocyte globulin; CTCAE, Common Terminology Criteria For Adverse Events; M, male; F, female; NS, non-severe;
S, severe; VS, very severe; CCI, Charlson Co-morbidity Index; COPD, chronic obstructive pulmonary disease; TIA, transient ischaemic attack;
CVA, cerebrovascular incident; TRALI, transfusion related acute lung injury; AML, acute myeloid leukaemia.
*Excluding fever, rigor and reversible hypotension during ATGAM infusion.
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the efficacy and safety of this treatment, a registry of adult
patients with aplastic anaemia who received ATGAM as first-
line treatment was started in 2012 in two university hospitals
(Leiden University Medical Centre and the Amsterdam Med-
ical Centre). In 2014, this registry formed the basis of a
national NVvH registry, in which seven Dutch University
Hospitals and two large non-academic hospitals collect data
on all consecutive adult aplastic anaemia patients receiving
IST with ATGAM and CSA as first-line treatment. Complete-
ness of patient cohorts per hospital was checked using deliv-
ery data for ATGAM to the hospital pharmacies. In March
2016, 55 consecutive patients were registered, of which 23
were aged ≥ 60 years at start of the treatment. Here we
report efficacy and toxicity of IST with standard dosed
ATGAM and CSA in this subgroup.
The median age of the 23 patients at start of the treatment
was 64 years and median follow-up time was 12 months
(Table I). Seventeen patients were evaluable for response at
6 months after treatment; 1 patient had died and 5 patients
had not reached the 6-month follow-up at the time of analysis.
One patient had a complete haematological response at
6 months and 9 patients had a partial response, defined as
transfusion independency and neutrophil count >05 9 109/l
(Table I). Overall survival after 6 and 12 months was 96% and
88% respectively (Table I, Fig S1). Comorbidity before the
start of IST was determined using the Charlson co-morbidity
index (Charlson et al, 1987) and toxicity during the admission
for ATGAM up to 1 month after treatment was graded using
(National Institute of Cancer Common Terminology Criteria
for Adverse Events criteria for all 23 patients (http://ctep.
cancer.gov/protocolDevelopment/electronic_applications/docs/
ctcaev3.pdf). Before start of IST, 15 patients had no significant
comorbidity, whereas 8 patients had a co-morbidity index
score ≥1 (Tables I and II). During admission for ATGAM
infusion, atrial fibrillation occurred in two patients, of whom
one had a history of aortic valve stenosis and developed
myocardial ischaemia related to the atrial fibrillation. Other
cardiac adverse events were angina pectoris (n = 1) and pro-
longed QTc interval (n = 1). During, or shortly after IST, 8
patients developed (partly) reversible kidney injury as a result
of CSA toxicity (Table II). One patient had a subdural haema-
toma, which resulted in epileptic seizure. During follow-up,
one patient died at 1 month due to a haemorrhagic stroke, 1
patient died at 10 months due to complications after second-
line alloSCT and one patient died at 45 months due to infec-
tious complications during treatment for secondary acute
myeloid leukaemia (Table II).
Based on this unselected consecutive cohort of elderly
patients with aplastic anaemia who received first-line treat-
ment with standardized IST consisting of ATGAM and CSA,
we conclude that in daily practice, this treatment leads to a 6-
month response rate of 59% in patients ≥60 years, which is
comparable to the response rates reported in previous studies
with younger adults (Scheinberg et al, 2009, 2011). Although
serious cardiac side effects were seen in 2 patients during and
shortly after treatment with ATGAM, the overall survival at
6 months is 96% (Fig S1). In our cohort, no clear correlation
can be seen between comorbidity before start of the treatment
and the efficacy and/or toxicity of the treatment.
We conclude that age should not be an absolute contra-
indication for treating elderly patients with acquired aplastic
anaemia with ATGAM combined with CSA. Prolongation of
the Dutch national registry and extended follow up of the
registered patients will provide knowledge on toxicity and
long-term efficacy of ATG-based IST in elderly patients.
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Supporting Information
Additional Supporting Information may be found in the
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Fig S1. Overall survival of aplastic anaemia patients ≥60
years treated with horse-derived anti-thymocyte globulin and
ciclosporin. Open circles represent censoring due to closure
of the dataset in March 2016 in order to perform the analysis
described in this manuscript. IST, immunosuppressive
therapy.
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